A three-protein signature can be used to differentiate between idiopathic pulmonary fibrosis (IPF) and other…
Articles by Marisa Wexler, MS
The Phase 3 REBUILD clinical trial, which tested Bellerophon Therapeutics‘ inhaled nitric oxide therapy INOpulse in people with…
The first participant has been dosed in a clinical trial testing the experimental anti-fibrotic therapy BBT-877 in people with…
ZEPHYRUS-2, the second Phase 3 clinical trial testing the experimental therapy pamrevlumab in people with idiopathic pulmonary fibrosis (IPF),…
Treatment with Nuformix’s experimental therapy NXP002 reduced markers of fibrosis, or tissue scarring, in a laboratory model of…
Black patients with pulmonary fibrosis (PF) are diagnosed around a decade earlier than their white counterparts in the U.S.,…
Being exposed at work to medium or high levels of asbestos is associated with a near double risk of developing…
The U.S. Food and Drug Administration (FDA) has granted INS018_055 orphan drug designation for the treatment of idiopathic pulmonary fibrosis…
The Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis (PF) has enrolled…
A new startup company called Isterian Biotech has launched with the goal of developing new therapies for fibrotic diseases. Isterian…